NCT05797077 is a Phase 3 clinical trial of Colorectal resection surgery. in Colorectal Cancer, sponsored by Sixth Affiliated Hospital, Sun Yat-sen University.

Who is sponsoring NCT05797077?

NCT05797077 is sponsored by Sixth Affiliated Hospital, Sun Yat-sen University.

What drugs are being tested in NCT05797077?

Interventions in NCT05797077: Colorectal resection surgery., FOLFOX chemotherapy regimen, Capecitabine.

What condition does NCT05797077 study?

NCT05797077 studies Colorectal Cancer, Liver Metastases, Circulating Tumor Cell, Cancer, Therapy-Related.

Is NCT05797077 still recruiting?

NCT05797077 is currently recruiting now. Last updated 4 April 2023.

Last reviewed 2023-04-04 · How we verify

NCT05797077

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Postoperation Maintenance Therapy for Resectable Liver Metastases of Colorectal Cancer Guided by ctDNA

Recruiting now Phase 3 Last updated 4 April 2023

What this trial tests

Phase 3 trial testing Colorectal resection surgery. in Colorectal Cancer in 346 participants. Currently enrolling.

Timeline

20 February 2023

Primary endpoint
20 February 2029

20 February 2031

Quick facts

Lead sponsor	Sixth Affiliated Hospital, Sun Yat-sen University
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	346
Start date	20 February 2023
Primary completion	20 February 2029
Estimated completion	20 February 2031
Sites	1 location across China

Drugs / interventions tested

Colorectal resection surgery.
FOLFOX chemotherapy regimen — full drug profile →
Capecitabine (capecitabine) — full drug profile →

Conditions studied

Colorectal Cancer — all drugs for Colorectal Cancer →
Liver Metastases — all drugs for Liver Metastases →
Circulating Tumor Cell — all drugs for Circulating Tumor Cell →
Cancer, Therapy-Related — all drugs for Cancer, Therapy-Related →

Sponsor

Sixth Affiliated Hospital, Sun Yat-sen University

Who can join

Adults 18 to 75, any sex, with Colorectal Cancer or Liver Metastases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to compare in resectable liver metastases colorectal cancer patients.The main question it aims to answer is to investigate whether the progression-free survival (PFS) of resectable colorectal liver metastasis (CRLM) patients with positive ctDNA after surgery is superior with the combination of adjuvant chemotherapy and maintenance therapy compared to adjuvant chemotherapy alone.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment.
Parikh AR, Chee BH, Tsai J, Rich TA, et al · · 2024 · cited 13× · PMID 38695832 · DOI 10.1158/1078-0432.ccr-23-3660
Optimizing Treatment Strategy for Oligometastases/Oligo-Recurrence of Colorectal Cancer.
Yokoi R, Tajima JY, Fukada M, Hayashi H, et al · · 2023 · cited 10× · PMID 38201569 · DOI 10.3390/cancers16010142
Clinical utility and future perspectives of liquid biopsy in colorectal cancer.
Patelli G, Lazzari L, Crisafulli G, Sartore-Bianchi A, et al · · 2025 · cited 7× · PMID 40275061 · DOI 10.1038/s43856-025-00852-4

Verify or expand the search:

Other recruiting trials for Colorectal Cancer

Currently open trials in the same condition.

NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting

Other Sixth Affiliated Hospital, Sun Yat-sen University trials

Trials by the same sponsor.

NCT07538284 — MInimizing Delirium With Nasal Dexmedetomidine-InducEd Sleep (MIDDIES) · Phase 2, PHASE3 · not yet recruiting
NCT07176182 — Clinical Trial of Neoadjuvant mFOLFOX Plus Alvenor for LARC Patients With High YWHAB Expression · Phase 2 · not yet recruiting
NCT07510191 — TNFi Plus Low-Dose Upadacitinib vs TNFi Intensification in Crohn's Disease With Suboptimal Response · Phase 4 · recruiting
NCT07344428 — Efficacy and Safety of CDED With Anti-TNF-α Biologics in Crohn's Disease: A Randomized Trial · NA · not yet recruiting
NCT07328958 — Effect of Titrated Administration of Ciprofol on Perioperative Hypotension in Elderly Patients Undergoing Laparoscopic A · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05797077 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sixth Affiliated Hospital, Sun Yat-sen University
Last refreshed: 4 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05797077.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing